Payers/Purchasers Engagement Clearinghouse

Lessons learned from the APhA Foundation

Lessons learned from the APhA Foundation

The FH Foundation’s FOCUS Report quantifies gaps in diagnosis and treatment, and the unfortunate corresponding cardiovascular event rates in individuals with familial hypercholesterolemia (FH). The new 2018 FOCUS Report includes healthcare encounter data from January - December 2018, from 45 of the largest health plans and other payers (for example, pharmacy benefit managers, self-insured employers)...The results are presented by types of insurance: Commercial, Medicare, or Other (for example, Medicaid). Data may be filtered by gender, race/ethnicity, age and by health plan/payer.

National Lipid Association Statement Paper Provides Clinicians with Updated Guidance for Enhanced Value of PCSK9 Use in Select Patient Populations

Article published in JAMA Cardiology evaluating patient access to PCSK9i among those prescribed therapy using pharmacy transaction data.

A checklist modeling processes for P&T Committees to consider when managing the formulary system in making equitable coverage decisions, focusing on evidence-based processes to select and promote treatments offering the best therapeutic outcomes, while minimizing potential risks and costs to patients.

Presented by FH Foundation and Patient Advocate Foundation

Copay Assistance programs can have positive benefits for patients but can drive up benefit plan costs. Some PBMs have introduced designs that offset both the positive and negative effects of these programs. This webcast will provide an overview of these designs, the potential benefits and risks associated with them and key considerations for a value-based approach.

FH expert, Dr. Dan Rader, will help us understand these treatment options, how they work, who they are FDA approved for, and what kind of results we might expect.